BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus price target of $8.50 for the company and are expecting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also assigned BrainStorm Cell Therapeutics an industry rank of 108 out of 265 based on the ratings given to related companies.
Separately, Maxim Group set a $5.00 price objective on shares of BrainStorm Cell Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 11th.
Shares of BrainStorm Cell Therapeutics (NASDAQ:BCLI) opened at 2.40 on Friday. The company has a 50 day moving average of $2.44 and a 200-day moving average of $2.43. The company’s market cap is $44.77 million. BrainStorm Cell Therapeutics has a 52-week low of $1.90 and a 52-week high of $3.87.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings data on Thursday, August 11th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.13. Analysts forecast that BrainStorm Cell Therapeutics will post ($0.34) EPS for the current fiscal year.
A hedge fund recently raised its stake in BrainStorm Cell Therapeutics stock. Vanguard Group Inc. increased its position in BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 1.3% during the second quarter, according to its most recent filing with the SEC. The fund owned 491,867 shares of the biotechnology company’s stock after buying an additional 6,200 shares during the period. Vanguard Group Inc. owned about 2.64% of BrainStorm Cell Therapeutics worth $1,186,000 as of its most recent SEC filing. Institutional investors own 8.74% of the company’s stock.
About BrainStorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BrainStorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainStorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.